AgomAb Therapeutics NV American Depositary Shares Cash Flow-to-Debt Ratio
AgomAb Therapeutics NV American Depositary Shares cash flow-to-debt ratio. AgomAb Therapeutics NV American Depositary Shares (AGMB) has a Cash Flow-to-Debt Ratio of -0.67x as of March 2026, meaning its operating cash flow of $-12.44 Million could theoretically repay -1% of its total liabilities ($18.70 Million) in one year. See financial agility of AgomAb Therapeutics NV American Deposita to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of AgomAb Therapeutics NV American Depositary Shares (2022–2025)
Cash flow-to-debt ratio of AgomAb Therapeutics NV American Depositary Shares from 2022 to 2025. Historical debt coverage capacity for AgomAb Therapeutics NV American Depositary Shares across 4 annual periods. Also explore AGMB net asset momentum to track the company's year-over-year net asset growth rate.
AgomAb Therapeutics NV American Depositary Shares Cash Flow-to-Debt Ratio by Year (2022–2025)
AgomAb Therapeutics NV American Depositary Shares cash flow-to-debt ratio by year from 2022 to 2025. Year-by-year debt coverage analysis for AgomAb Therapeutics NV American Depositary Shares. For the full cash flow conversion analysis, see AgomAb Therapeutics NV American Deposita operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.27x | $-51.74 Million | $22.80 Million | ▲ +11.4% |
| 2024 | -2.56x | $-46.83 Million | $18.28 Million | ▼ -106.5% |
| 2023 | -1.24x | $-24.59 Million | $19.82 Million | ▼ -127.3% |
| 2022 | -0.55x | $-18.97 Million | $34.75 Million | — |